Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

NCT06112340 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Thyroid Eye Disease
Graves Orbitopathy
Endocrine System Diseases
Eye Diseases
Thyroid Associated Ophthalmopathy
Graves Ophthalmopathy
Thyroid Diseases
Orbital Diseases
Proptosis
IGF1R
Exophthalmos
Hashimoto

Interventions

DRUG: linsitinib

Sponsor

Sling Therapeutics, Inc.